<DOC>
	<DOCNO>NCT01924689</DOCNO>
	<brief_summary>This protocol examine safety intratumoral administration Clostridium Novyi-NT spores patient treatment-refractory solid tumor malignancy . This investigational study measure anti-tumor activity C. novyi-NT administer intratumoral patient treatment-refractory solid tumor malignancy .</brief_summary>
	<brief_title>Safety Study Intratumoral Injection Clostridium Novyi-NT Spores Treat Patients With Solid Tumors That Have Not Responded Standard Therapies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Diagnosis advance solid tumor malignancy . There must target tumor measureable , palpable clearly identifiable ultrasound radiographic guidance amenable percutaneous injection C. novyiNT spore . The targeted lesion must longest diameter ≥ 1 cm ≤ 12 cm measurable defined RECIST 1.1 criterion . The target lesion must locate either thoracic , abdominal pelvic cavity brain . There must clinical , functional , radiographic evidence bone involvement site target lesion . 2 . History prior treatment least one line systemic anticancer therapy , approve systemic therapy available , curative option available continued treatment . 3 . At least 4 week elapse since completion major surgery , patient fully recover surgery postsurgical complication . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less . 5 . Patient least 18 year age . 6 . Patient capable give informed consent . 7 . Patient childbearing potential ( defined clinical site ' standard ) use adequate birth control measure ( e.g. , barrier method spermicide ; intrauterine device ; implantable injectable hormonal contraceptive ; surgical sterilization ) duration study continue use precaution 12 month receive treatment . 8 . Patient significant valvular heart disease ( trace mild valvular stenosis regurgitation allow ) . 9 . Patient able stay within 45 minute drive time emergency room 28 day . 10 . The patient caregiver 28 day dose . 1 . Positive pregnancy test . 2 . Serum creatinine level &gt; 1.5 x upper limit normal ( ULN ) , chronic renal failure require hemodialysis peritoneal dialysis . 3 . Patient follow hematologic parameter : Platelet count equal less 100,000/mm3 Hemoglobin less 9.0 g/dL Absolute neutrophil count ( ANC ) less 1,000 /mm3 4 . Oxygen saturation ( Sp02 ) less 95 % room air . 5 . Mean arterial blood pressure ( BP ) less 70 mmHg . 6 . Glasgow Coma Score ( GCS ) less 15 . 7 . Treatment investigational drug within past 30 day 5 halflives drug , whichever short . 8 . Documented primary brain malignancy brain metastasis . 9 . Clinically significant ascites clinical evidence history portosystemic hypertension cirrhosis . 10 . Laboratory evidence hepatic dysfunction indicate follow : Bilirubin ≥ 1.5 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2.5X ULN Alkaline phosphatase 2.5X ULN International normalize ratio ( INR ) great 1.3 11 . Patient foreign body opinion treat investigator could difficult manage case infection ( e.g . prosthetic hip ) . 12 . Clinically significant pleural effusion . 13 . Clinically significant pericardial effusion , circumferential pericardial effusion , effusion great 1.0 cm location around heart . 14 . Need ongoing treatment immunosuppressive agent . 15 . History solid organ transplantation ( exception corneal transplant &gt; 3 month prior screen ) . 16 . History ischemic insult previous 12 month ( myocardial infarction , cerebral vascular accident , ischemic tissue injury , transient ischemic attack . 17 . History significant medical illness deem PI local investigator unsuitable trial . For example : i. Symptomatic congestive heart failure ii . Psychiatric Illness/social situation may make study dangerous iii . Unstable angina pectoris 18 . Asplenia . 19 . Antibiotic allergy would preclude treatment C. novyiNT infection . 20 . Treatment antibiotic within 2 week ( 14 day ) dose . 21 . Active clinically significant systemic localize infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Metastatic Disease</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Metastases</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Necrosis</keyword>
	<keyword>Intratumoral</keyword>
	<keyword>Locally advanced cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Chordoma</keyword>
	<keyword>Bacteriolytic</keyword>
</DOC>